deferoxamine has been researched along with Hypertension, Pulmonary in 5 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Strict lifelong adherence to the standard transfusion and deferoxamine therapy reduces considerably the occurrence of heart failure, LV dysfunction and pericarditis, prevents early heart failure and pulmonary hypertension, but does not eliminate completely cardiac disease in patients with thalassemia major." | 3.72 | Cardiac status in well-treated patients with thalassemia major. ( Aessopos, A; Diamanti-Kandaraki, E; Farmakis, D; Fragodimitri, C; Hatziliami, A; Joussef, J; Karabatsos, F; Karagiorga, M; Meletis, J; Mitilineou, E, 2004) |
| "We report a case of successful treatment of pulmonary hypertension in a patient with beta-thalassemia major and review the literature on pulmonary hypertension and beta-thalassemia major." | 1.33 | Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. ( Farber, HW; Tam, DH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mokhtar, GM | 1 |
| Tantawy, AA | 1 |
| Adly, AA | 1 |
| Ismail, EA | 1 |
| Wong, CM | 1 |
| Preston, IR | 1 |
| Hill, NS | 1 |
| Suzuki, YJ | 1 |
| Aessopos, A | 1 |
| Farmakis, D | 1 |
| Hatziliami, A | 1 |
| Fragodimitri, C | 1 |
| Karabatsos, F | 1 |
| Joussef, J | 1 |
| Mitilineou, E | 1 |
| Diamanti-Kandaraki, E | 1 |
| Meletis, J | 1 |
| Karagiorga, M | 1 |
| Tam, DH | 1 |
| Farber, HW | 1 |
| Dessouroux, A | 1 |
| Akwa, Y | 1 |
| Baulieu, EE | 1 |
5 other studies available for deferoxamine and Hypertension, Pulmonary
| Article | Year |
|---|---|
Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Chelation Therapy; | 2011 |
Iron chelation inhibits the development of pulmonary vascular remodeling.
Topics: Animals; Blood Proteins; Case-Control Studies; Cell Proliferation; Cells, Cultured; Deferoxamine; Fe | 2012 |
Cardiac status in well-treated patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cardiac Output; Child; Deferoxamine; Echocar | 2004 |
Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.
Topics: Adult; Antihypertensive Agents; beta-Thalassemia; Deferoxamine; Dyspnea; Epoprostenol; Hemosiderosis | 2006 |
DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension.
Topics: Amino Acids, Dicarboxylic; Base Sequence; Cells, Cultured; Cobalt; Deferoxamine; Dehydroepiandroster | 2008 |